Skip to main content

Advertisement

Table 1 Baseline characteristics of enrolled patients and Cox survival analysis for risk of HCC

From: Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data

Variables Valuea Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender, female 47 (18.7%) 0.524(0.271–1.014) 0.055 0.566(0.290–1.105) 0.095
Age(years) 47.4 (45.9–48.9) 1.009(0.991–1.028) 0.337   
ALT (IU/L), <40 114     
40–160 82 1.534(0.773–3.047) 0.221   
> = 160 46 1.234(0.597–2.550) 0.571   
TBA(μmol/L), <10 84     
10–100 91 2.267(1.324–3.882) 0.003 1.918(1.111–3.310) 0.019
> = 100 68 2.218(1.231–3.997) 0.008 1.654(0.897–3.053) 0.107
APRI, <0.5 40     
0.5–1.5 79 0.815(0.424–1.568) 0.541   
> = 1.5 110 1.304(0.825–2.061) 0.256   
DNA(IU/ml), <5a102 136     
5a102–106 44 1.421(0.608–3.320) 0.417   
> = 106 23 1.819(0.742–4.459) 0.191   
HBsAg, positive 198 0.529(0.244–1.147) 0.107   
HBeAg, positive 46 1.425(0.654–3.103) 0.373   
PIVKA-II(mAU/ml), <200 169 0.402(0.260–0.621) 0.000 0.433(0.277–0.678) 0.000
AFP(ng/ml), <20 115     
20–200 72 0.641(0.379–1.087) 0.099 0.611(0.357–1.045) 0.072
> = 200 42 0.700(0.391–1.251) 0.228 0.754(0.411–1.383) 0.362
  1. ALT alanine aminotransferase, TBA total bile acid, APRI aspartate aminotransferase to platelet ratio index, HBsAg hepatitis B surface antigen, HBeAg hepatitis B e antigen, PIVKA-II, protein induced by vitamin K absence-II, AFP alpha-fetoprotein
  2. aSome values were missing